COMPARATIVE EFFICACY OF ETODOLAC AND PLACEBO IN RHEUMATOID ARTHRITIC PATIENTS

  • 1 January 1982
    • journal article
    • research article
    • Vol. 20  (5) , 240-245
Abstract
Patients [24] with active rheumatoid arthritis were studied in a 4-wk, double-blind, placebo-controlled, parallel group trial. They were treated with a low dose (25, 50 and 100 mg twice daily) or high dose (100, 200 or 300 mg twice daily) of etodolac or with placebo. In both groups, 4 patients received placebo and 8 received the active drug in a fixed-titration regimen. Doses were increased weekly and kept at the highest level during the last 2 wk. Clinical and laboratory assessments were completed before drug and on days 8, 15 and 29. Seventeen patients completed 29 days and 7 discontinued the study earlier: 6 on placebo and 1 on low dose. Etodolac-low dose was significantly more effective than placebo in 9 of 10 clinical assessments and in all 10 at high dose. Etodolac was well tolerated. All patients had negative tests for occult blood at all times. Etodolac was an effective antiinflammatory agent and appeared to be safe in doses of 50-600 mg/day.

This publication has 1 reference indexed in Scilit: